Premiere Date: June 20, 2017
Expiration Date: December 20, 2018
This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
To understand the connection between fatigue and depression and the extent to which residual symptoms of fatigue can lead to worsened outcomes.
At the end of this CE activity, participants should be able to:
• Understand the many causes of fatigue and its connection to MDD
• Identify and categorize fatigue symptoms associated with depressive episodes
• Differentiate fatigue symptoms related to MDD from those that are related to another psychiatric disorder or a medical condition, or those that result from medication adverse effects
• Describe the primary tools available to measure fatigue in depression
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Steven D. Targum, MD, reports that he is a grant recipient from Johnson and Johnson PRD, Sunovion, Pfizer Inc, Acadia Pharmaceuticals, Alkermes Inc, and Intracellular Therapeutics Inc; he has received research support from Bracket Global LLC; he is a consultant for Neurim Pharmaceuticals, Methylation Sciences Inc, and Resilience Therapeutics; and he is a shareholder in Bracket LLC, Prana Biotechnology Ltd, Methylation Sciences Inc, and Functional Neuromodulation Inc.
Leslie Swanson, PhD, (peer/content reviewer) has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
Dr. Targum is Scientific Director of Bracket Global LLC in Boston, MA.
1. Walker EA, Katon WJ, Jemelka RP. Psychiatric disorders and medical care utilization among people in the general population who report fatigue. J Gen Intern Med. 1993;8:436-440.
2. Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry. 1984;41:934-941.
3. Tylee A, Gastpar M, Lépine J-P, Mendlewicz J. Identification of depressed patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) survey. Int Clin Psychopharmacol. 1999;14:153-165.
4. Targum SD, Hassman H, Pinho M, Fava M. Development of a clinical global impression scale for fatigue. J Psychiatric Res. 2012;46:370-374.
5. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomat Med. 2007;69:587-596.
6. Trivedi MH, Greer TL, Church TS, et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry. 2011;72:677-684.
7. Marin H, Menza MA. Treatment of residual fatigue in depressed patients. Psychiatry. 2004;1:12-18.
8. Struder HK, Weicker H. Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance: part II. J Sports Med. 2001;22:482-497.
9. Targum SD, Fava M, Alphs LD, et al. Fatigue across the CNS spectrum: a clinical review. Fatigue Biomed Health Behav. 2014;2:231-246.
10. DeBattista, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind placebo controlled study. J Clin Psychiatry. 2003;64:1057-1064.
11. Fava M, Thase ME, DeBattista C, et al. Modanifil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19:153-159.
12. Lam JY, Freeman MK, Cates ME. Modanifil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann Pharmacother. 2007;41:1005-1012.
13. Goodnick PJ, Sandoval R, Brickman A, Klimas NG. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry. 1992;32:834-838.
14. Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatric Res. 2006;40:370-373.
15. Wheaton AG, Perry GS, Chapman DP, Croft JB. Sleep disordered breathing and depression among U.S. adults: National Health and Nutrition Examination Survey, 2005-2008. Sleep. 2012;35:461-467.